



Moorfields
Eye Hospital
NHS Foundation Trust



Ophthalmic Formulary

March 2026

Version 1.48

Medicines Information Publication

(Click to) **BEGIN**

Ophthalmic Formulary

NICE

As part of the good practice guidance released by the **National Institute for Health and Care Excellence (NICE)**, every NHS organisation was expected to develop and update a local formulary, which would be made available on the internet from the 1st April 2013.

The aim of the formulary was to:

- Reflect local needs
- Reduce variation in prescribing
- Allow rapid uptake of innovative medicines and treatments (i.e. NICE recommendations)

Features:

1. **Accessibility** - Everything should be easily accessible from this document. You'll find relevant web links and internal documents (available only to Moorfields Eye Hospital)
2. **Contents page** - Simply by clicking the drug category, you'll be taken directly to the relevant section. Above and below each page are links, which direct you to the contents page.
3. **Relevant resources** – e.g. MEH anti-infective guidelines can be found at the end of each drug category.

Quick Links (Click on tab)

[Contents Page](#)

[Instructions](#)

Contents

(Click on drug category to continue)

Infection

Antiamoebic
Antibacterial
Antifungal
Antiviral
Tapeworm

Anti-inflammatory & Adjuncts

Corticosteroids
NSAIDs
Immunosuppressants
Miscellaneous
Antihistamines

Glaucoma

Mydriatic & Vasoconstrictor

Mydriatic
Vasoconstrictor

Cytotoxic

Ocular Lubricants & Other Eye Drop Preparations

Ocular Lubricants
Other (eye drop) preparations

Neovascularisation

Neurological

Botulinum
Systemic

Diagnostic & Surgical

Dye
Antiseptic
Irrigation
General Anaesthesia & Gases
Local Anaesthetic
Viscosurgical
Surgical (other)

Other (Systemic)

Bisphosphonates
Gastro-intestinal
Analgesics
Nutrition
Thyroid Dysfunction

Appendix 1. Fact Sheets

Press for Contents Page

Instructions

Antibacterial Infection

Bacterial Endophthalmitis (November 2005)

Cornea and External Disease Induction Manual - Bacterial keratitis page 45

Glaucoma service handbook

Guidelines for management of endophthalmitis, viral retinitis/acute retinal necrosis, toxoplasma chorioretinitis

Antimicrobial Guidelines

Under each sub-heading you'll find a list of relevant sources

| Drug Name | P/L ¹ | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------------------------------------|------------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|---------------------------|-------------------------------------------|
| azithromycin 2.5% eye drops | ■ | Antibacterial | Bacterial & Mycobacteria keratitis | | ✓ | | |
| eye drops | ■ | Antibacterial | Ocular Chlamydia infections; blepharitis | | ✓ | July 2012 DTC | |
| | ■ | Antibacterial | Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis | | ✓ | | |
| | ■ | Antibacterial | Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis; blebitis; bleb-related endophthalmitis | | ✓ | | |
| drops | ■ | Antibacterial | bacterial conjunctivitis; ophthalmia neonatorum; bacterial endophthalmitis; post-op prophylaxis; post intravitreal prophylaxis; | | ✓ | | |
| drops | ■ | Antibacterial | corneal abrasion; dacryocystitis; canaliculitis; suture removal | | ✓ | EYKAPPO multi-dose bottle | |
| chlorAMphenicol 0.5% single use eye drops | ■ | Antibacterial | Bacterial Conjunctivitis | | ✓ | | |
| chlorAMphenicol 1% eye ointment | ■ | Antibacterial | Bacterial Blepharitis | | ✓ | | |
| Clarithromycin 1% eye drops | ■ | Antibacterial | Mycobacterial keratitis | | | | |
| Clarithromycin 2% eye drops | ■ | Antibacterial | | | | | |
| dexamethasone 0.05% with framycetin 0.5% with gramicidin 0.005% eye/ear drops | ■ | Antibacterial | Uninfected inflammatory conditions of the anterior segment where development of bacterial infection is possible | | | | BNF 11.3.1; MEH Anti-infective Guidelines |
| erythromycin 0.5% eye ointment | ■ | al | Chlamydial conjunctivitis & trachomatis | | | | |
| fusidic acid 1% eye drops | ■ | al | infections due to Staphylococcus (usually in pregnant women) | | | ed April 2017 | |
| framycetin 0.5% solution for donor eyes | | | | | | | |
| gentamicin 0.3% eye drops | ■ | Antibacterial | | | | | |
| gentamicin 0.3% eye drops (preservative-free) | ■ | Antibacterial | Bacterial keratitis | | | | |
| gentamicin 1.5% FORTE eye drops | ■ | Antibacterial | | | | | |
| gentamicin 1.5% FORTE eye drops (preservative-free) | ■ | Antibacterial | | | | | |
| levofloxacin 0.5% eye drops | ■ | Antibacterial | Bacterial conjunctivitis; bacterial, sterile & mycobacterial keratitis; bleb-related endophthalmitis; blebitis; intraocular & periocular surgery; suture removal; post intravitreal injections; corneal abrasions | | ✓ | DTC Oct 2007 | |

▼ This medicine is monitored intensively by the UK safety regulators – the MHRA and CHM.

P/L – Product License
 ■ Unlicensed
 ■ Product License

N – National Guideline
 L – Local (MEH) Guideline
 ✓ Local or National Guidelines Exists

Trust Formulary Approval

BNF 11.3.1; MEH Anti-infective Guidelines

Relevant Sources

- Blank Page -

Infection

Antiamoebic

Antibacterial

Antifungal

Antiviral

Tapeworm

Primary Source

MEH Anti-infective Guidelines

Secondary Source

Adnexal Service Manual

Toxoplasmosis – Out of Hour Policy

Toxoplasma Chorioretinitis (TCR) Guidelines for Moorfields Casualty Department

Paediatric Orbital Cellulitis Guidelines

Antiamoebic Infection

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------|------|-------------|----------------------------------------------------------------------------------------------------------------------------|----|----|-----------------------|-------------------------------------------------------------------------------------|
| chlorHEXidine digluconate 0.02% eye drops | ■ | Antiamoebic | Acanthamoeba keratitis; antiseptic in patients with povidone iodine allergy (replaced with chlorhexidine 0.05%) | | ✓ | | MEH Anti-infective Guidelines; Cornea and External Disease Induction Manual page 51 |
| chlorHEXidine digluconate 0.05% eye drops | ■ | Antiamoebic | As an antiseptic option for intravitreal anti-VEGF injections and implants in those intolerant to povidone iodine. | | ✓ | DTC approved Feb 2019 | |
| hexamidine 0.1% eye drops | ■ | Antiamoebic | Acanthamoeba keratitis | | ✓ | | MEH Anti-infective Guidelines |
| polihexanide 0.02% eye drops | ■ | Antiamoebic | | | ✓ | | MEH Anti-infective Guidelines, Cornea and External Disease Induction Manual page 51 |
| polihexanide 0.06% eye drops | ■ | Antiamoebic | | | ✓ | | MEH Anti-infective Guidelines |
| proPAMidine 0.1% eye drops | ■ | Antiamoebic | | | ✓ | | MEH Anti-infective Guidelines; BNF 64 11.3.1 |
| | ■ | Antiamoebic | | | ✓ | | |

Antibacterial Infection

Bacterial Endophthalmitis (November 2005)

Cornea and External Disease Induction Manual - Bacterial keratitis page 45

Glaucoma service handbook

Guidelines for management of endophthalmitis, viral retinitis/acute retinal necrosis, toxoplasma chorioretinitis

Antimicrobial Guidelines

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source | |
|-------------------------------------------------------------------------------|------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|------------------------|-------------------------------------------|--|
| amikacin 2.5% eye drops | ■ | Antibacterial | Bacterial & Mycobacteria keratitis | | ✓ | | BNF 11.3.1; MEH Anti-infective Guidelines | |
| azithroMYCin 1.5% single use eye drops | ■ | Antibacterial | Ocular chlamydia infections; blepharitis | | ✓ | DTC approved July 2012 | | |
| cefTAZidime 5% eye drops | ■ | Antibacterial | Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis | | ✓ | | | |
| cefUROxime 5% eye drops | ■ | Antibacterial | Neisseria conjunctivitis; ophthalmia neonatorum; bacterial keratitis; blebitis; bleb-related endophthalmitis | | ✓ | | | |
| chlorAMPhenicol 0.5% eye drops | ■ | Antibacterial | bacterial conjunctivitis; ophthalmia neonatorum; bacterial endophthalmitis; post-op prophylaxis; post intravitreal prophylaxis; corneal abrasion; dacryocystitis; canaliculitis; suture removal | | ✓ | | | |
| chlorAMPhenicol 0.5% eye drops (preservative-free bottle) | ■ | Antibacterial | | | | ✓ | | |
| chlorAMPhenicol 0.5% single use eye drops | ■ | Antibacterial | | | | ✓ | | |
| chlorAMPhenicol 1% eye ointment | ■ | Antibacterial | Bacterial Blepharitis | | ✓ | | | |
| CLArithromycin 1% eye drops | ■ | Antibacterial | Mycobacterial keratitis | | | | | |
| CLArithromycin 2% eye drops | ■ | Antibacterial | | | | | | |
| dexamethasone 0.05% with framycetin 0.5% with gramicidin 0.005% eye/ear drops | ■ | Antibacterial | Uninfected inflammatory conditions of the anterior segment where development of bacterial infection is possible | | | | | |
| erythromycin 0.5% eye ointment | ■ | Antibacterial | Chlamydial conjunctivitis & trachomatis | | ✓ | | | |
| fusidic acid 1% eye drops | ■ | Antibacterial | Infections due to Staphylococcus (usually in pregnant women) | | ✓ | Removed April 2017 | | |
| framycetin 0.5% solution for donor eyes | | | | | | | | |
| gentamicin 0.3% eye drops | ■ | Antibacterial | Bacterial keratitis | | ✓ | | | |
| gentamicin 0.3% eye drops (preservative-free) | ■ | Antibacterial | | | | | | |
| gentamicin 1.5% FORTE eye drops | ■ | Antibacterial | | | | | | |
| gentamicin 1.5% FORTE eye drops (preservative-free) | ■ | Antibacterial | | | | | | |
| levoFLOXacin 0.5% eye drops | ■ | Antibacterial | Bacterial conjunctivitis; bacterial, sterile & mycobacterial keratitis; bleb-related endophthalmitis; blebitis; intraocular & periocular surgery; suture removal; post intravitreal injections; corneal abrasions | | ✓ | DTC approved Oct 2007 | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------------------------|------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|------------------------|-------------------------------------------|
| moxifloxacin 0.5% eye drops | ■ | Antibacterial | Bacterial conjunctivitis; bacterial, sterile & mycobacterial keratitis; bleb-related endophthalmitis; blebitis; intraocular & periocular surgery; suture removal; post intravitreal injections; corneal abrasions | | ✓ | DTC approved July 2012 | BNF 11.3.1; MEH Anti-infective Guidelines |
| penicillin 0.3% eye drops | ■ | Antibacterial | Bacterial keratitis | | ✓ | | |
| vancomycin 1.4% eye drops | ■ | Antibacterial | Boston K-pro antibiotic prophylaxis | | ✓ | May 2012 | |
| vancomycin 5% eye drops | ■ | Antibacterial | Bacterial keratitis | | ✓ | | |
| cefUROxime 1mg in 0.1mL intracameral prefilled syringe (Aprokam) | ■ | Antibacterial | Prophylaxis during intraocular and periocular surgery | | ✓ | DTC approved Oct 2011 | BNF 5.1; MEH Anti-infective Guidelines |
| amikacin 0.4mg in 0.1mL intravitreal injection pre-pack | ■ | Antibacterial | Bacterial endophthalmitis | | ✓ | | |
| vancomycin 2mg in 0.1mL intravitreal injection pre-pack | ■ | Antibacterial | | | ✓ | | |
| amikacin 500mg in 2mL injection | ■ | Antibacterial | Bacterial endophthalmitis when intravitreal pre-pack unavailable | | ✓ | | |
| amoxicillin 250mg injection | ■ | Antibacterial | | | ✓ | | |
| amoxicillin 500mg injection | ■ | Antibacterial | | | ✓ | | |
| benzylpenicillin 600mg injection | ■ | Antibacterial | Necrotising fasciitis | | ✓ | | |
| cefTAZidime 1g injection | ■ | Antibacterial | Bacterial endophthalmitis | | ✓ | | |
| cefTAZidime 2g injection | ■ | Antibacterial | | | ✓ | | |
| cefTRlaxone 1g injection | ■ | Antibacterial | Neisseria conjunctivitis; ophthalmia neonatorum; orbital cellulitis | | ✓ | | |
| cefTRlaxone 2g injection | ■ | Antibacterial | | | ✓ | | |
| cefUROxime 250mg injection | ■ | Antibacterial | Prophylaxis prior to complex adnexal procedures | | ✓ | | |
| cefUROxime 750mg injection | ■ | Antibacterial | | | ✓ | | |
| ciprofloxacin 100mg in 50mL infusion | ■ | Antibacterial | Bacterial endophthalmitis; orbital cellulitis; necrotising fasciitis | | ✓ | | |
| CLArithromycin 500mg injection | ■ | Antibacterial | | | ✓ | | |
| CLINdamycin 300mg in 2mL injection | ■ | Antibacterial | Orbital cellulitis (with ciprofloxacin), necrotising fasciitis (with ciprofloxacin & benzylpenicillin) | | ✓ | | |
| CLINdamycin 300mg in 2mL injection | ■ | Antibacterial | As an option in the treatment of toxoplasmosis: clindamycin intravitreal injection 1mg in 0.1 mL STAT +/- dexamethasone intravitreal injection 400 micrograms in 0.1 mL STAT, as required up to 5 injections in 6 weeks. | | ✓ | DTC approved Feb 2019 | |
| erythromycin lactobionate 1g injection | ■ | Antibacterial | | | ✓ | | |
| flucLOxacillin 250mg injection | ■ | Antibacterial | Orbital cellulitis | | ✓ | | |
| flucLOxacillin 500mg injection | ■ | Antibacterial | | | ✓ | | |
| gentamicin 80mg in 2mL injection | ■ | Antibacterial | | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------|------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|----------|----------------------------------------|
| metroniDAzole 500mg in 100mL infusion | ■ | Antibacterial | orbital cellulitis (with ceftriaxone & flucloxacillin) | | ✓ | | BNF 5.1; MEH Anti-infective Guidelines |
| spECTinomycin 2g injection | ■ | Antibacterial | Neisseria conjunctivitis | | ✓ | | |
| teicoplanin 200mg injection | ■ | Antibacterial | Patients positive or at high risk of MRSA - prophylaxis in surgery | | ✓ | | |
| vancomycin 500mg injection | ■ | Antibacterial | Bacterial endophthalmitis when intravitreal pre-pack unavailable | | ✓ | | |
| amoxicillin 125mg in 5mL sugar free suspension | ■ | Antibacterial | | | ✓ | | |
| amoxicillin 250mg capsules | ■ | Antibacterial | | | ✓ | | |
| amoxicillin 250mg in 5mL sugar free suspension | ■ | Antibacterial | | | ✓ | | |
| amoxicillin 3g sugar free sachet | ■ | Antibacterial | | | ✓ | | |
| azithroMYCin 200mg in 5mL suspension | ■ | Antibacterial | Blebitis & bleb-related endophthalmitis (with moxifloxacin), toxoplasmosis | | ✓ | | |
| azithroMYCin 250mg capsules | ■ | Antibacterial | | | ✓ | | |
| azithroMYCin 250mg tablets | ■ | Antibacterial | | | ✓ | | |
| azithroMYCin 500mg tablets | ■ | Antibacterial | | | ✓ | | |
| cefACLor 250mg in 5mL suspension | ■ | Antibacterial | Post-operative complex procedures; pre-septal cellulitis; lid lacerations | | ✓ | | |
| cefALExin 125mg in 5mL suspension | ■ | Antibacterial | | | ✓ | | |
| cefALExin 250mg capsules | ■ | Antibacterial | | | ✓ | | |
| cefALExin 250mg in 5mL suspension | ■ | Antibacterial | | | ✓ | | |
| cefALExin 250mg tablets | ■ | Antibacterial | | | ✓ | | |
| cefUROxime 125mg tablets | ■ | Antibacterial | | | ✓ | | |
| ciprofloxacin 250mg in 5mL suspension | ■ | Antibacterial | Bacterial endophthalmitis (with clarithromycin) | | ✓ | | |
| ciprofloxacin 250mg tablets | ■ | Antibacterial | | | ✓ | | |
| ciprofloxacin 500mg tablets | ■ | Antibacterial | | | ✓ | | |
| ciprofloxacin 750mg tablets | ■ | Antibacterial | | | ✓ | | |
| CLArithromycin 250mg tablets | ■ | Antibacterial | Bacterial endophthalmitis (with ciprofloxacin), soft tissue infection, preseptal cellulitis, lid lacerations, orbital blow out fractures, periocular abscesses (with metronidazole) | | ✓ | | |
| CLArithromycin 250mg/5mL suspension | | | | | | | |
| CLINdamycin 150mg capsules | ■ | Antibacterial | Toxoplasmosis | | ✓ | | BNF 5.1; MEH Anti-infective Guidelines |
| CLINdamycin 75mg/5mL suspension | ■ | | | | | | |
| co-amOXIclav 125/31 sugar free suspension | ■ | Antibacterial | Blebitis (& moxifloxacin); preseptal cellulitis; lid lacerations; orbital blow out fractures; periocular abscesses (with metronidazole), dacrycystitis (with chloramphenicol); sinusitis | | ✓ | | |
| co-amOXIclav 250/62 sugar free suspension | ■ | Antibacterial | | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------|------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----|-----------|-----------------------------------------------------------------------------------------------|
| co-amOXiclav 375mg tablets | ■ | Antibacterial | | | ✓ | | |
| co-amOXiclav 625mg tablets | ■ | Antibacterial | | | ✓ | | |
| cofluampicil 250/250 capsules | ■ | Antibacterial | | | ✓ | | |
| co-trimoxazole 480mg tablets | ■ | Antibacterial | | Prophylaxis of toxoplasmosis | | ✓ | |
| dapsone 100mg tablets | ■ | Antibacterial | Treatment of ocular cicatricial pemphigoid and cicatrizing conjunctivitis in linear IgA disease | | ✓ | | BNF 5.1; MEH Anti-infective Guidelines; Cornea and External Disease Induction Manual page 175 |
| dapsone 50mg tablets | ■ | Antibacterial | | | ✓ | | |
| doxycycline 50mg capsules | ■ | Antibacterial | Chlamydial conjunctivitis, blepharitis, chalazia | | ✓ | | BNF 5.1; MEH Anti-infective Guidelines |
| erythromycin 125mg in 5mL suspension | ■ | Antibacterial | Blepharitis, soft tissue infection, preseptal cellulitis, lid lacerations, orbital blow out fractures, periocular abscesses (with metronidazole) | | ✓ | | |
| erythromycin 250mg in 5mL sugar free suspension | ■ | Antibacterial | | | ✓ | | |
| erythromycin 250mg tablets | ■ | Antibacterial | | | ✓ | | |
| ethambutol 100mg tablets | ■ | Antibacterial | | | ✓ | | |
| flucLOxacillin 125mg in 5mL syrup | ■ | Antibacterial | Soft tissue infection | | ✓ | | |
| flucLOxacillin 250mg capsules | ■ | Antibacterial | | | ✓ | | |
| flucLOxacillin 250mg in 5mL syrup | ■ | Antibacterial | | | ✓ | | |
| flucLOxacillin 500mg capsules | ■ | Antibacterial | | | ✓ | | |
| isoniazid 100mg tablets | ■ | Antibacterial | | | ✓ | | |
| isoniazid 50mg tablets | ■ | Antibacterial | | | ✓ | | |
| metroniDAZole 200mg in 5mL suspension | ■ | Antibacterial | Preseptal cellulitis (with co-amoxiclav or cefalexin) | | ✓ | | |
| metroniDAZole 200mg tablets | ■ | Antibacterial | | | ✓ | | |
| moxifloxacin 400mg tablets | ■ | Antibacterial | Bacterial endophthalmitis, mycobacterial keratitis (with clarithromycin), blebitis. (All unlicensed indications) | | ✓ | July 2009 | |
| ofloxacin 400mg tablets | ■ | Antibacterial | | | ✓ | | |
| phenOXYmethylpenicillin 125mg in 5mL solution | ■ | Antibacterial | | | ✓ | | |
| phenOXYmethylpenicillin 250mg in 5mL solution | ■ | Antibacterial | | | ✓ | | |
| phenOXYmethylpenicillin 250mg tablets | ■ | Antibacterial | | | ✓ | | |
| pyriMETHamine 25mg tablets | ■ | Antibacterial | Toxoplasmosis (with sulfadiazine and folinic acid) | | ✓ | | BNF 5.1; MEH Anti-infective Guidelines |
| rifampicin 150mg with isoniazid 100mg tablets | ■ | Antibacterial | | | ✓ | | |
| rifampicin 300mg with isoniazid 150mg tablets | ■ | Antibacterial | | | ✓ | | |
| rifampicin 300mg capsule | ■ | Antibacterial | | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------------------|------|---------------|------------------------------------------------------------------------------------------------|----|----|----------|------------------|
| rifampicin 100mg/5mL suspension | ■ | | | | ✓ | | |
| spirAMYcin 1g tablets | ■ | Antibacterial | Infections due to toxoplasmosis in pregnant women | | ✓ | | |
| sulfaDIAzine 500mg tablets | ■ | Antibacterial | Toxoplasmosis (with pyrimethamine and folinic acid) | | ✓ | | |
| tetraCYcline 250mg tablets | ■ | Antibacterial | Blepharitis (long term treatment) | | ✓ | | |
| triMETHoprim 200mg tablets | ■ | Antibacterial | | | ✓ | | |
| chlorhexidine 0.1% with neomycin sulphate 0.5% nasal cream | ■ | Antibacterial | MRSA eradication if allergy to mupirocin | | ✓ | | |
| mupirocin 2% nasal ointment | ■ | Antibacterial | MRSA | | ✓ | | |
| fusidic acid 2% cream | ■ | Antibacterial | | | ✗ | | |
| fusidic acid 2% ointment | ■ | Antibacterial | | | ✗ | | |
| hydrocortisone acetate 1% with fusidic acid 2% ointment | ■ | Antibacterial | | | ✓ | | |
| Octenisan antimicrobial wash lotion | ■ | Antibacterial | | | ✓ | | |
| ciprofloxacin 0.3% eye ointment | ■ | Antibacterial | Restricted use – only used for prevention of infection in OOKP (Osteo-Odonto-Keratoprosthesis) | | ✓ | | DTC October 2022 |

Antifungal Infection

Cornea and External Disease Induction Manual - Fungal keratitis

Guidelines for management of endophthalmitis, viral retinitis/acute retinal necrosis, toxoplasma chorioretinitis

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------------------------------------------------|------|------------|---------------------------------------------|----|----|--------------------------|-------------------------------|
| amphotericin 0.15% eye drops | ■ | Antifungal | <i>Candida</i> fungal infections; keratitis | | ✓ | | MEH Anti-infective Guidelines |
| chlorHEXidine digluconate 0.2% eye drops | ■ | Antifungal | Fungal keratitis | | ✓ | DTC approved Aug 2011 | |
| cloTRImazole 1% eye drops | ■ | Antifungal | Anti-fungal eye drop | | ✗ | No longer available | |
| miCONazole 1% eye drops | ■ | Antifungal | <i>Candida</i> fungal infections; keratitis | | ✗ | No longer available | MEH Anti-infective Guidelines |
| natamycin 5% eye drops | ■ | Antifungal | Fungal Keratitis | | ✓ | JFC Approved May 2013 | |
| voriconazole 1% eye drops | ■ | Antifungal | Fungal infection | | ✓ | DTC Approved August 2011 | |
| amphotericin 5 micrograms in 0.1mL intravitreal injection pre-pack | ■ | Antifungal | Fungal endophthalmitis | | ✓ | | |
| amphotericin 50mg deoxycholate injection | ■ | Antifungal | Fungal infection | | ✓ | | |
| amphotericin 50mg liposomal injection | ■ | Antifungal | Fungal infection | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------------------------|------|------------|---------------------------------------------|----|----|-------------------------------------------------------------|-------------------------------|
| flucONAzole 200mg in 100mL infusion | ■ | Antifungal | Fungal infection | | ✓ | | |
| voriconazole 200mg infusion | ■ | Antifungal | Fungal endophthalmitis; keratitis | | ✓ | Powder for solution diluted and injected intravitreally | |
| flucONAzole 200mg capsules | ■ | Antifungal | Fungal endophthalmitis, keratitis (Candida) | | ✓ | | |
| flucONAzole 50mg capsules | ■ | Antifungal | | | | | |
| flucONAzole 50mg in 5mL suspension | ■ | Antifungal | | | | | |
| flucYTosine 500mg tablets | ■ | Antifungal | Last resort for fungal infections | | ✓ | Pre-dates DTMMC | |
| itraconazole 100mg capsules | ■ | Antifungal | Fungal keratitis (Aspergillus) | | ✓ | | |
| nystatin 100,000 units in 1mL suspension | ■ | Antifungal | Oral fungal infection | | ✓ | | |
| terBINafine 250mg tablets | ■ | Antifungal | Fungal infection | | ✓ | | |
| voriconazole 200mg tablets | ■ | Antifungal | Fungal Endophthalmitis, keratitis | | ✓ | Sep 2003 Consultant only (Medical Retina or Vitreo-Retinal) | |
| voriconazole 50mg tablets | ■ | Antifungal | | | | | |
| miconazole 2% with hydrocortisone 1% cream | ■ | Antifungal | Fungal skin infection | | ✓ | | MEH Anti-infective Guidelines |
| miconazole 2% cream | ■ | Antifungal | Fungal skin infection | | ✓ | | MEH Anti-infective Guidelines |

Antiviral Infection

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------|------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|------------|---------------------------------------------------------------------------------------|
| aciclovir 3% eye ointment | ■ | Antiviral | <i>Herpes simplex virus</i> - restricted use only; when ganciclovir 0.15% eye gel is contraindicated e.g. complicated pregnancy. Please refer to MEH Anti-infective Guidelines | | ✓ | | MEH Anti-infective Guidelines |
| ganciclovir 0.15% eye gel | ■ | Antiviral | <i>Herpes simplex virus</i> - 1 st line | | ✓ | | |
| triFLUorothymidine 1% eye drops | ■ | Antiviral | <i>Herpes simplex virus</i> - 2 nd line | | ✓ | | |
| foscarnet 24mg in 1ml injection | ■ | Antiviral | Cytomegalovirus retinitis | | ✓ | | MEH Anti-infective Guidelines; |
| ganciclovir 4.5mg intravitreal implant | ■ | Antiviral | CMV retinitis in patients with AIDS and those who have undergone organ transplants or using immunosuppressive agents for collagen diseases. | | ✓ | April 2008 | Guidelines for management of endophthalmitis, viral retinitis/acute retinal necrosis, |
| aciclovir 250mg injection | ■ | Antiviral | Acute retinal necrosis | | ✓ | | |
| aciclovir 500mg injection | ■ | Antiviral | | | | ✓ | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------|------|------------|--------------------------------------------------------------------------------|----|----|---------------|---------------------------------------------------------------------------|
| aciclovir 200mg in 5mL sugar free suspension | ■ | Antiviral | | | ✓ | | toxoplasma chorioretinitis, with guidance for sample processing |
| aciclovir 200mg tablets | ■ | Antiviral | Herpes simplex conjunctivitis, keratitis | | ✓ | | |
| aciclovir 400mg tablets | ■ | Antiviral | Herpes simplex conjunctivitis, keratitis; Bell's Palsy | | ✓ | | |
| aciclovir 800mg dispersible tablets | ■ | Antiviral | Acute Retinal Necrosis | | ✓ | | |
| famciclovir 250mg tablets | ■ | Antiviral | | | ✓ | | |
| oseltamivir 12mg in 1mL oral suspension | ■ | Antiviral | | | ✓ | | |
| oseltamivir 30mg capsules | ■ | Antiviral | | | ✓ | | |
| oseltamivir 45mg capsules | ■ | Antiviral | | | ✓ | | |
| oseltamivir 75mg capsules | ■ | Antiviral | | | ✓ | | |
| valACiclovir 500mg tablets | ■ | Antiviral | Varicella Zoster Virus, Herpes Retinitis, Acute Retinal Necrosis; Bell's Palsy | | ✓ | December 2006 | MEH Anti-infective Guidelines; Cornea & External Disease Induction Manual |
| valGANciclovir 450mg tablets | ■ | Antiviral | CMV retinitis induction and maintenance treatment. | | ✓ | April 2008 | |

Tapeworm Infections

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|---------------------------|------|---------------|------------------------------------|----|----|----------|-------------------------------|
| aIBENdazole 400mg tablets | ■ | Anthelmintics | Microsporium (Used with Fumadil-B) | | ✓ | | MEH Anti-infective Guidelines |

Anti-inflammatory & Adjuncts

Corticosteroids

NSAIDs

Immunosuppressant

Immunomodulating

Antihistamines

Corticosteroids

Cornea and External Disease Induction Manual
Adnexal Service Handbook

| Drug Name | P/L [†] | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------------------------------------------------------|------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----|-----------------------------|-------------------------------------------------------------------------------------------------------|
| betamethasone 0.1% / neomycin 0.5% eye/ear/nose drops | ■ | Steroid | Uninfected inflammatory conditions of the anterior segment where development of bacterial infection is possible | | ✓ | | Moorfields Pharmacists Handbook; Cornea and External Disease Induction Manual; Adnexal Service Manual |
| betamethasone 0.1% eye ointment | ■ | Steroid | Inflammation in anterior segment; post-operatively to reduce inflammation | | ✓ | | |
| betamethasone 0.1% eye/ear/nose drops | ■ | Steroid | | | ✓ | | |
| dexamethasone 0.1% eye drops | ■ | Steroid | | | ✓ | | |
| dexamethasone 0.1% eye drops (preservative-free bottle) | ■ | Steroid | | | ✓ | | |
| dexamethasone 0.1% single use eye drops | ■ | Steroid | | | ✓ | | |
| dexamethasone 0.1% with neomycin 0.35% with polymyxin B sulphate 6,000 units in 1g eye ointment | ■ | Steroid | | Uninfected inflammatory conditions of the anterior segment where development of bacterial infection is possible | | ✓ | |
| dexamethasone 0.1% with neomycin 0.35% with polymyxin B sulphate 6,000 units in 1mL eye drops | ■ | Steroid | | | ✓ | | |
| fluoROMetholone 0.1% eye drops | ■ | Steroid | Inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe | | ✓ | | |
| hydrocortisone sodium phosphate 0.335% eye drops | ■ | Steroid | (i) Treatment of mild non-infectious allergic or inflammatory conjunctival diseases. (licensed) (ii) Treatment of mild non-infectious allergic or inflammatory ocular surface diseases. (off-label) (iii) Minimising of ocular surface scar tissue formation. (off-label use) | | ✓ | JFC approved September 2019 | |
| hydrocortisone ointment 0.5% | ■ | Steroid | Atopic dermatitis | ✓ | | | NICE eczema |
| hydrocortisone ointment 1% | | | | | | | |
| hydrocortisone cream 0.5% | | | | | | | |
| hydrocortisone Cream 1% | | | | | | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------|------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|----------------------------------------|-------------------------------------------------------------------------------------------------------|
| loTEPrednol etabonate 0.5% eye drops | ■ | Steroid | Inflammation in anterior segment | | ✓ | DTC approved January 2010 | Moorfields Pharmacists Handbook; Cornea and External Disease Induction Manual; Adnexal Service Manual |
| prednisolone 0.001% eye drops | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.003% eye drops | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.01% eye drops | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.01% eye drops (preservative-free bottles) | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.03% eye drops | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.03% eye drops (preservative-free bottles) | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.1% eye drops | ■ | Steroid | | | ✓ | | |
| prednisolone 0.1% eye drops (preservative-free bottles) | ■ | Steroid | | | ✓ | | |
| prednisolone 0.3% eye drops | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.3% eye drops (preservative-free bottles) | ■ | Steroid | | | ✓ | Discontinued | |
| prednisolone 0.5% eye/ear drops | ■ | Steroid | | | ✓ | | |
| prednisolone 0.5% single use eye drops | ■ | Steroid | | | ✓ | | |
| prednisolone 1% eye drops | ■ | Steroid | | | ✓ | | |
| RIMexolone 1% eye drops | ■ | Steroid | Hypertensive uveitis | | ✓ | Nov 2008 Discontinued | |
| dexamethasone 2mg tablets | ■ | Steroid | | | ✓ | | |
| methyIPREDnisolone 2mg, 4mg, 16mg and 100mg tablets | ■ | Steroid | Multiple sclerosis associated optic neuritis, non-MS associated optic neuritis, chronic relapsing inflammatory optic neuropathy and chronic relapsing inflammatory optic neuropathy in neuromyelitis optica | ✓ | ✓ | May 2012 Formulary | NICE Multiple sclerosis |
| prednisolone 1mg tablets | ■ | Steroid | Systemic anti-inflammatory | | ✓ | | |
| prednisolone 2.5mg enteric-coated tablets | ■ | Steroid | | | ✓ | | |
| prednisolone 25mg tablets | ■ | Steroid | | | ✓ | | |
| prednisolone 5mg enteric-coated tablets | ■ | Steroid | | | ✓ | | |
| prednisolone 5mg soluble tablets | ■ | Steroid | | | ✓ | October 2016 switched to oral solution | |
| prednisolone 5mg tablets | ■ | Steroid | | | ✓ | | |
| prednisolone 1mg/mL oral solution | ■ | Steroid | | | ✓ | | |
| beclometasone 50 microgram aqueous nasal spray | ■ | Steroid | | | | ✓ | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------------------------------------------|------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| betamethasone sodium phosphate 4mg in 1mL injection | ■ | Steroid | | | ✓ | | |
| dexamethasone 0.7mg intravitreal implant | ■ | Steroid | Treatment of macular oedema following central retinal vein occlusion. Treatment of macular oedema following branch retinal vein occlusion when: treatment with laser photocoagulation has not been beneficial or treatment with laser photocoagulation is not considered suitable because of extent of macular haemorrhage. Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis. DMO Treatment of posterior uveitis in patients under the age of 18 | ✓ | ✓ | July 2011; NCL JFC Jan 13 | NICE Dexamethasone Intravitreal Implant Technology Appraisal; MEH Ozurdex (dexamethasone implant); NCL JFC Jan 13 Minutes NICE TA DMO NICE TA Non-infectious uveitis DTMMC Jan 2025 |
| dexamethasone 3.3mg in 1mL injection HOSPIRA | ■ | Steroid | | | ✓ | | |
| dexamethasone base 3.3mg in 1mL injection | ■ | Steroid | | | ✓ | | |
| dexamethasone base 4mg in 1mL injection | ■ | Steroid | | | ✓ | | |
| dexamethasone phosphate 8mg in 2mL injection | ■ | Steroid | | | ✓ | | |
| fluocinolone acetonide 190 mcg intravitreal implant | ■ | Steroid | Chronic diabetic macular oedema after an inadequate response to prior therapy. As per NICE TA 301 Preventing relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. As per NICE TA 590 Treatment of posterior uveitis in patients under the age of 18 | ✓ | ✓ | NICE TA 301 Nov 2013 (replaced by NICE TA 953 March 2024) NICE TA 590 July 2019 DTMMC Jan 2025 | NICE Technology Appraisal |
| hydrocortisone sodium succinate 100mg injection | ■ | Steroid | | | ✓ | | |
| methylPREDnisolone acetate 40mg in 1mL injection | ■ | Steroid | | | ✓ | | |
| methylPREDnisolone sodium succinate 40mg injection | ■ | Steroid | | | ✓ | | |
| methylPREDnisolone sodium succinate 500mg injection | ■ | Steroid | Multiple sclerosis associated optic neuritis, non-MS associated optic neuritis, chronic relapsing inflammatory optic neuropathy and chronic relapsing inflammatory optic neuropathy in neuromyelitis optica | ✓ | ✓ | May 2012 Formulary | NICE Multiple sclerosis |
| methylPREDnisolone sodium succinate 1g injection | ■ | Steroid | | ✓ | ✓ | | |
| triAMCinolone acetonide 40mg in 1mL injection (Kenalog®) | ■ | Steroid | A licensed product but used off-label in the following indications: Uveitic macular oedema refractory to other treatment modalities and diabetic macular oedema refractory to other treatment modalities. Progressive visual loss from macular oedema secondary to AMD, vascular occlusions and 'pseudo-phakic macula oedema' hypotony maculopathy' | | ✓ | DTC approved October 2007 Consultant Only | Kenolog in Medical Retina Service |
| triAMCinolone acetonide 40 mg in 1 mL ophthalmic suspension injection (Intracinal®) | ■ | Steroid | A licensed medical device but used off-label in the prophylaxis and treatment of cystoid macular oedema (CMO) secondary to non-infectious uveitis | | | DTC approved August 2020 Uveitis Service | |
| difluprednate 0.05% eye drops | ■ | Steroid | Chronic macular oedema and uveitic macular oedema | | ✓ | DTC Jan 2022 | |

NSAIDS

| Drug Name | P/L [†] | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------------------------------|------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|----------|---------------------------------------------|
| diclofenac sodium 0.1% single use eye drops | ■ | NSAIDs | (i) inhibition of peroperative miosis during cataract surgery (ii) Treatment of post-operative inflammation, pain and discomfort (iii) relief of ocular signs and symptoms of seasonal allergic conjunctivitis | | ✓ | | BNF 11.8; Moorfields Pharmacists Handbook |
| ketoROLac 0.5% eye drops | ■ | NSAIDs | (i) Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery (licensed) (ii) Inflammation in the anterior segment (off-label) | | ✓ | | |
| diclofenac sodium 75mg in 3mL injection | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 100mg modified release tablets | ■ | NSAIDs | Pain and inflammation | | ✓ | | BNF 10.1.1; Moorfields Pharmacists Handbook |
| diclofenac sodium 25mg enteric coated tablets | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 50mg dispersible tablets | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 50mg enteric coated tablets | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 100mg suppositories | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 12.5mg suppositories | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 25mg suppositories | ■ | NSAIDs | | | ✓ | | |
| diclofenac sodium 50mg suppositories | ■ | NSAIDs | | | ✓ | | |
| ibuprofen 400mg tablets | ■ | NSAIDs | | | ✓ | | |
| meFENamic acid 250mg capsules | ■ | NSAIDs | | | ✓ | | |
| flurbiprofen 50mg coated tablets | ■ | NSAIDs | | | ✓ | | |
| meLOXicam 15mg tablets | ■ | NSAIDs | | | ✓ | | |
| naPROxen 250mg tablets | ■ | NSAIDs | | | ✓ | | |
| piroxicam 20mg tablets | ■ | NSAIDs | | | ✓ | | |

Immunosuppressant

Cornea and External Disease Induction Manual

Adnexal Service Handbook

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source | |
|------------------------------------------------------------------|------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|----|-------------------------------------------------|---------------------------------------------------------------------------------------|--|
| ciclosporin 0.2% eye ointment | ■ | Immunosuppressive | 1. Severe allergic eye disease: Atopic Keratoconjunctivitis (AKC) & Vernal Keratoconjunctivitis (VKC) (off-label but approved for use in primary care by NCL JFC) 2. Dry Eye Disease (DED)/ Keratoconjunctivitis Sicca (KCS) 3. Blepharo-keratoconjunctivitis (BKC) / Ocular Rosacea (off-label but approved for use in primary care by NCL JFC) 4. Thygeson's keratitis & Chronic graft versus host disease (off-label but approved for use in primary care by NCL JFC) | | ✓ | DTC approved July 2012 JFC approved Oct 2015 | Moorfields Pharmacists Handbook NCL MON Ciclosporin Eye Preparations Factsheet | |
| ciclosporin 1mg/mL eye drops (IKERVIS®) | ■ | Immunosuppressive | | | | | | |
| ciclosporin 1mg/mL eye drops (VERKAZIA®) licensed in paediatrics | ■ | Immunosuppressive | 1. Severe Vernal Keratoconjunctivitis (VKC) in children from 4 years of age and adolescents 2. Severe Atopic Keratoconjunctivitis (AKC) (off-label) 3. Dry Eye Disease (DED)/ Keratoconjunctivitis Sicca (KCS) (off-label) 4. Blepharo-keratoconjunctivitis (BKC) / Ocular Rosacea (off-label) 5. Thygeson's keratitis & Chronic graft versus host disease (off-label) | | ✓ | DTC approved Feb 2019 | NCL MON Ciclosporin Eye Preparations Factsheet | |
| azathioprine 25mg tablets | ■ | Immunosuppressive | Non-infectious intermediate, posterior or pan-uveitis and retinal vasculitis | | ✓ | | Cornea and External Disease Induction Manual page 123 | |
| azathioprine 50mg tablets | ■ | Immunosuppressive | Scleritis | | ✓ | | | |
| ciclosporin 100mg capsules | ■ | Immunosuppressive | Steroid sparing agent in uveitis: Intermediate, posterior or pan-uveitis Retinal vasculitis of non-infectious origin Refractory non-infectious childhood uveitis Scleritis | | ✓ | | Cornea and External Disease Induction Manual page 135 | |
| ciclosporin 100mg in 1mL solution | ■ | Immunosuppressive | | | | ✓ | | |
| ciclosporin 25mg capsules | ■ | Immunosuppressive | | Acathamoeba sclerokeratitis, atopic sclerokeratitis | | ✓ | | |
| ciclosporin 50mg capsules | ■ | Immunosuppressive | Keratitis: ulcerative keratitis, Thygeson's superficial punctuate keratitis Corneal transplants at high risk of rejection Keratoconjunctivitis, Atopic keratoconjunctivitis, vernal keratoconjunctivitis, ligneous keratoconjunctivitis Rheumatoid corneal melt and corneal melt associated with other causes of systemic vasculitis Mooren's ulcer | | ✓ | | Cornea and External Disease Induction Manual page 135 | |
| cyclophosphamide 50mg tablets | ■ | Immunosuppressive | Necrotising scleritis, rarely for the management of uveitis in younger patients; destructive corneal disease, ocular cicatricial pemphigoid, | | ✓ | | Cornea and External Disease Induction Manual 164 | |

| | | | | | | | |
|--------------------------------------------|---|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------|-------------------------------------------------------|
| | | | idiopathic orbital inflammation, Wegener's granulomatosis and Thyroid eye disease: probably not favourable. | | | | |
| methoTREXate 2.5mg tablets | ■ | Immunosuppressive | Uveitis | ✓ | Jan 2011 | Medical Retina Service Guidelines page 64; Policy for Oral Methotrexate | |
| methoTREXate 2mg/mL solution | ■ | Immunosuppressive | | ✓ | Aug 2023 DTC | | |
| methoTREXate 7.5mg in 0.15mL pen | ■ | Immunosuppressive | Macular oedema in uveitis patients who cannot have steroids | | | | |
| methoTREXate 10mg in 0.2mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 12.5mg in 0.25mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 15mg in 0.3mL pen | ■ | Immunosuppressive | | ✓ | | BNOS Guideline PCNSL | |
| methoTREXate 17.5mg in 0.35mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 20mg in 0.4mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 22.5mg in 0.45mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 25mg in 0.5mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 27.5mg in 0.55mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 30mg in 0.6mL pen | ■ | Immunosuppressive | | | | | |
| methoTREXate 50mg in 1mL pen | ■ | Immunosuppressive | | | | | |
| mycophenolate mofetil 250mg capsules | ■ | Immunosuppressive | | Steroid sparing agent. Uveitis, Scleritis: Limited experience, mycophenolate has been used for JIA associated uveitis, non-infectious intermediate-, posterior- or panuveitis and retinal vasculitis as well as for different types of scleritis. | ✓ | | Cornea and External Disease Induction Manual page 151 |
| mycophenolate mofetil 500mg tablets | ■ | Immunosuppressive | ✓ | | | MHRA Drug Safety Update: new pregnancy-prevention advice for women and men | |
| mycophenoLIC acid 360mg tablets | ■ | Immunosuppressive | ✓ | | | | |
| mycophenolate mofetil 1g in 5mL suspension | ■ | Immunosuppressive | ✓ | | | | |
| sirolimus 1mg tablets | ■ | Immunosuppressive | Corneal allograft recipients at high risk of rejection, in whom calcineurin antagonists are not tolerated or ineffective in prevention of rejection. | ✓ | Dec 2004 | Cornea and External Disease Induction Manual page 194 | |
| sulfasalazine 500mg tablets | ■ | Immunosuppressive | Pemphigoid | ✓ | | Cornea and External Disease Induction Manual page 60 | |
| sulfasalazine 250mg in 5ml suspension | ■ | Immunosuppressive | Pemphigoid | ✓ | | Cornea and External Disease Induction Manual page 60 | |

| | | | | | | | |
|-----------------------------------|---|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|---|--|-------------------------------------------------------|
| tacrolimus 1mg capsules | ■ | Immunosuppressive | Steroid sparing agent and uveitis, scleritis (sight-threatening uveitis of non-infectious origin – including non respondersto cyclosporine or cannot tolerate side effects. | | ✓ | | Cornea and External Disease Induction Manual page 181 |
| tacrolimus 500 microgram capsules | ■ | Immunosuppressive | | | ✓ | | |
| tacrolimus 5mg capsules | ■ | Immunosuppressive | | | ✓ | | |
| tacrolimus 0.03%/0.1% ointment | ■ | Immunosuppressive | Ocular surface application for vernal keratoconjunctivitis or atopic keratoconjunctivitis. Steroid sparing agent in patients with atopic eye conditions in patients who are either intolerant or unresponsive to topical ciclosporin | | ✓ | | To be initiated by external disease consultant only |
| | | | Use on skin including face and lid for atopic dermatitis | ✓ | | | Preparation is not sterile Nice TA [TA 82] |

Miscellaneous

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-----------------------------------------------------|------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|-----------------------------------------------------------------------|----------------------------------------------------|
| interferon alfa-2b 1 million units in 1ml eye drops | ■ | Immunomodulating | Corneal and conjunctival intraepithelial neoplasias | | ✓ | Discontinued DTC approved May 2012 | |
| Adalimumab 40mg solution for injection | ■ | Cytokine modulator | Posterior uveitis Non-infectious uveitis | | ✓ | Sep 2013 JFC NICE TA July 2017 | NICE TAG460 Non-infectious uveitis |
| Infliximab solution for infusion | ■ | Cytokine modulator | Acute or chronic refractory ocular inflammation in patients non-responsive to systemic immunosuppressive treatment (unlicensed indication). Orbital inflammation and severe corneal and conjunctival inflammatory disease (unlicensed indication). | | ✓ | April 2008 DTC & Nov 2009 DTC Not to be administered at MEH | |
| Infliximab pre-filled pen | ■ | Cytokine modulator | Acute or chronic refractory ocular inflammation in patients non-responsive to systemic immunosuppressive treatment (unlicensed indication). Orbital inflammation and severe corneal and conjunctival inflammatory disease (unlicensed indication). | | ✓ | July 2021 DTC Subcutaneous injection | |
| Rituximab | ■ | Cytokine modulator | Mucus membrane pemphigoid | | ✓ | DTC Jan 2015 | IV administration at St Thomas Intravitreal |
| | | | Posterior uveitis, scleritis and refractory panuveitis | | ✓ | DTC April 2018 | |
| | | | Vitreoretinal lymphoma | | ✓ | DTC July 2021 | |
| Tocilizumab solution for infusion | ■ | Cytokine modulators | Posterior uveitis, scleritis and refractory panuveitis | | ✓ | DTC April 2018 | IV administration at St Thomas |
| Tocilizumab solution for injection | ■ | Cytokine modulators | Posterior uveitis, scleritis and refractory panuveitis | | ✓ | DTC April 2018 | |

Antihistamines

Cornea and External Disease Induction Manual

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source | |
|------------------------------------------------------------------------|------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------|----|----|---------------------------------|-----------------------------------------------------------------------------------|---------------------|
| emedastine 0.05% eye drops | ■ | Antihistamine | Seasonal allergic conjunctivitis | | ✓ | | BNF 11.1.1; Moorfields Pharmacists Handbook <i>page 132</i> | |
| loDOXamide 0.1% eye drops | ■ | Antihistamine | Allergic conjunctivitis | | ✓ | | | |
| ketotifen 0.25mg in 1mL single use eye drops | ■ | Antihistamine | Seasonal allergic conjunctivitis as a second line after olopatadine in those allergic to preservatives | | ✓ | DTC April 2019 JFC July 2019 | | |
| nedocromil sodium 2% eye drops | ■ | Antihistamine | Allergic conjunctivitis; vernal keratoconjunctivitis | | ✓ | Discontinued | | |
| olopatadine 1mg in 1mL eye drops | ■ | Antihistamine | Seasonal allergic conjunctivitis | | ✓ | Approved June 2003 | | |
| sodium CROMoglycate 2% eye drops | ■ | Antihistamine | Allergic conjunctivitis; vernal keratoconjunctivitis | | ✓ | | BNF 11.1.1; Moorfields Pharmacists Handbook <i>page 132</i> | |
| sodium CROMoglycate 2% eye drops (preservative free bottle) | ■ | Antihistamine | | | | ✗ | | No longer available |
| sodium CROMoglycate 2% single use eye drops | ■ | Antihistamine | | | | ✓ | | DTC July 2010 |
| cetirizine 10mg tablets | ■ | Antihistamine | Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria | | ✓ | | BNF 3.4 | |
| cetirizine 5mg in 5mL solution | ■ | Antihistamine | | | | ✓ | | |
| chlorPHEnamine 2mg in 5mL syrup | ■ | Antihistamine | Symptomatic relief of allergy such as hay fever, urticaria | | ✓ | | | |
| chlorPHEnamine 4mg tablets | ■ | Antihistamine | | | | ✓ | | |
| chlorPHEnamine 10mg in 1mL injection | ■ | Antihistamine | Emergency treatment of anaphylactic reactions | ✓ | ✓ | | | |
| loraTIDine 10mg tablets | ■ | Antihistamine | Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria | | ✓ | | BNF 3.4.1, 4.1.1 & 4.6; Emergency treatment of anaphylactic reactions; NICE CG134 | |
| proMETHazine 10mg tablets | ■ | Antihistamine | Symptomatic relief of allergy such as hay fever, urticaria; emergency treatment of anaphylactic reactions; sedation; nausea and vomiting | ✓ | ✓ | | | |
| proMETHazine 25mg tablets | ■ | Antihistamine | | | ✓ | ✓ | | |
| proMETHazine 5mg in 5mL elixir | ■ | Antihistamine | | | ✓ | ✓ | | |
| proMETHazine 25mg in 1mL injection | ■ | Antihistamine | | | ✓ | ✓ | | |

Glaucoma

NICE Glaucoma Guidelines Glaucoma Service Handbook

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------|------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|--------------------------------------------------|-----------------------------------------------------|
| acetazolamide 250mg in 5mL suspension | ■ | Glaucoma | Open and narrow angle glaucoma | | ✓ | | |
| acetazolamide 250mg modified release capsules | ■ | Glaucoma | | | ✓ | Discontinued | |
| acetazolamide 250mg tablets | ■ | Glaucoma | | | ✓ | | |
| acetazolamide 500mg injection | ■ | Glaucoma | Primary acute angle closure. Open and narrow angle glaucoma | | ✓ | | |
| apraclonidine 0.5% eye drops | ■ | Glaucoma | Short-term reduction of elevated intraocular pressure in chronic open angle glaucoma; some patients may benefit from long term use. Used in maximum tolerated therapy to delay surgery or laser therapy. Horner's Syndrome test | | ✓ | | Glaucoma Service Handbook; |
| apraclonidine 1% eye drops single use eye drops | ■ | Glaucoma | To lower intraocular pressure in patient: Uncontrolled intraocular pressure (IOP) on maximum medical treatment; Allergy to preservatives in eye drops; Visual acuity less than 6/60 in fellow eye; Ocular surface disease or previous corneal surgery; High risk of surgical morbidity; Patient unwilling to undergo glaucoma surgery | | ✓ | January 2012 DTMMC Initiation by Consultant Only | |
| betAXOlol 0.25% eye drops | ■ | Glaucoma | Open angle glaucoma & ocular hypertension | ✓ | ✓ | | NICE Glaucoma Guidelines; Glaucoma Service Handbook |
| betAXOlol 0.25% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| bimatoprost 0.03% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | DTC Sep 2007 | |
| bimatoprost 0.03% with timolol 0.5% single use eye drops | ■ | Glaucoma | | | | | |
| bimatoprost 0.1mg in 1mL eye drops | ■ | Glaucoma | | ✓ | ✓ | July 2010 DTC | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|---------------------------------------------------------------------|------|---------------------|-------------------------------------------|---------------------------------------------------------------------------------|----|-----------------------------------------------------------------------------------------|-------------------------|
| bimatoprost 0.3mg in 1mL eye drops | ■ | Glaucoma | | ✓ | ✓ | Not available | |
| bimatoprost 0.3mg in 1mL single use eye drops | ■ | Glaucoma | | ✓ | ✓ | Joint Formulary Committee Apr 2013 | |
| brimonidine 0.2% eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| brimonidine 0.2% with brinzolamide 1% eye drops | ■ | Glaucoma | | ✓ | ✓ | Aug 2015 DTC | |
| brimonidine 0.2% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | Sep 2005 DTC | |
| brinzolamide 1% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | July 2009 DTC | |
| briNZolamide 10mg in 1mL eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| carTEOLOl 1% eye drops | ■ | Glaucoma | | ✗ | ✗ | | Discontinued March 2017 |
| carTEOLOl 2% eye drops | ■ | Glaucoma | | ✗ | ✗ | | Discontinued March 2017 |
| dorzolamide 2% eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| dorzolamide 2% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | Feb 2005 DTC | |
| dorzolamide 2% preservative-free multidose bottle | ■ | Glaucoma | | ✓ | ✓ | | |
| dorzolamide 2% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | Feb 2005 DTC | |
| dorzolamide 2% with timolol 0.5% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| dorzolamide 2% with timolol 0.5% preservative-free multidose bottle | ■ | Glaucoma | | ✓ | ✓ | | |
| glycerol 50% oral solution | ■ | Glaucoma | | Short-term reduction of elevated intraocular pressure in angle-closure glaucoma | | ✓ | |
| latanoprost 0.005% eye drops | ■ | Glaucoma | Open angle glaucoma & ocular hypertension | ✓ | ✓ | December 2006 Prescriptions signed by Consultant staff within the Glaucoma Service only | |
| latanoprost 0.005% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | Joint Formulary Committee Apr 2013 | |
| latanoprost 0.005% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | December 2006 (Consultant's signature only) | |
| latanoprost 0.005% with timolol 0.5% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | August 2019 DTC | |
| latanoprost 0.005% with netarsudil 0.02% eye drops | ■ | Glaucoma | | | ✓ | August 2023 DTC | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------------|------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|----|--------------|--------|
| levoBUNolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | Discontinued | |
| levoBUNolol 0.5% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| mannitol 10% infusion | ■ | Glaucoma | Rapid reduction of elevated intraocular pressure especially during acute angle closure | | ✓ | | |
| mannitol 20% infusion | ■ | Glaucoma | | | ✓ | | |
| Pilocarpine 0.1% eye drops | ■ | Glaucoma | | | | | |
| pilocarpine 0.25% eye drops | ■ | Glaucoma | Open angle and other forms of chronic glaucoma | | ✓ | | |
| pilocarpine 1% eye drops | ■ | Glaucoma | Open angle and other forms of chronic glaucoma | ✓ | ✓ | | |
| pilocarpine 1% eye drops (preservative-free bottle) | ■ | Glaucoma | | | ✓ | | |
| pilocarpine 2% eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| pilocarpine 2% eye drops (preservative-free bottle) | ■ | Glaucoma | | | ✓ | | |
| pilocarpine 2% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| pilocarpine 4% eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| pilocarpine 4% eye drops (preservative-free bottle) | ■ | Glaucoma | Open angle and other forms of chronic glaucoma | | ✓ | | |
| pilocarpine 6% eye drops | ■ | Glaucoma | | | ✓ | | |
| pilocarpine 6% eye drops (preservative-free bottle) | ■ | Glaucoma | | | ✓ | | |
| timolol 0.1% eye drops single use eye gel | ■ | Glaucoma | | Open angle glaucoma & ocular hypertension | ✓ | ✓ | |
| timolol 0.25% eye drops | ■ | Glaucoma | Open angle glaucoma & ocular hypertension. Sublingually in patients with an osteo-odonto-keratoprosthesis (OOKP) to control intraocular pressure where intra-ocular pressure cannot be measured accurately and desired effect is not achieved from topical therapy | ✓ | ✓ | | |
| timolol 0.25% eye drops (preservative free bottle) | ■ | Glaucoma | | | | ✓ | Eysano |
| timolol 0.25% eye gel (LA) | ■ | Glaucoma | Open angle glaucoma & ocular hypertension | ✓ | ✓ | | |
| timolol 0.25% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| timolol 0.5% eye gel (LA) | ■ | Glaucoma | Open angle glaucoma & ocular hypertension | ✓ | ✓ | | |
| timolol 0.5% single use eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| travoprost 0.04% with timolol 0.5% eye drops | ■ | Glaucoma | | ✓ | ✓ | DTC Sep 2007 | |
| travoprost 40 microgram in 1mL eye drops | ■ | Glaucoma | | ✓ | ✓ | | |
| travoprost 40 microgram in 1mL single use eye drops | ■ | Glaucoma | | | ✓ | DTC Aug 2023 | |

Mydriatic & Vasoconstrictor

Mydriatic

Vasoconstrictor

Mydriatic

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------------------------------------|------|------------|-----------------------------------------------------------------------------------------------------------------------------------------|----|----|--------------------------|----------------------------------------------------------------|
| atropine 0.1% eye drops | ■ | Mydriatic | To slow myopia progression in children and young people | | ✓ | No longer available | DTMMC September 2019 |
| atropine 0.05% eye drops | ■ | Mydriatic | | | ✓ | Added by Chair's actions | Updated formulary request provided 4 th August 2020 |
| atropine 0.01% eye drops | ■ | Mydriatic | | | ✓ | | DTMMC September 2019 |
| atropine 1% eye drops | ■ | Mydriatic | Mydriasis and cycloplegia; Refraction in children; Occlusion. To relieve severe pain due to ciliary muscle spasm e.g. painful blind eye | | ✓ | | Moorfields Pharmacists Handbook |
| atropine 1% eye drops (preservative free bottle) | ■ | Mydriatic | | | ✗ | No longer available | |
| atropine 1% single use eye drops | ■ | Mydriatic | | | ✓ | | |
| cyclopentolate 0.5% eye drops | ■ | Mydriatic | Mydriasis and cycloplegia | | ✓ | | Moorfields Pharmacists Handbook |
| cyclopentolate 0.5% single use eye drops | ■ | Mydriatic | | | ✓ | | |
| cyclopentolate 1% eye drops | ■ | Mydriatic | | | ✓ | | |
| cyclopentolate 1% eye drops (preservative free bottle) | ■ | Mydriatic | | | ✗ | No longer available | |
| cyclopentolate 1% single use eye drops | ■ | Mydriatic | | | ✓ | | |
| homatropine 1% eye drops | ■ | Mydriatic | | | ✗ | No longer available | |
| homatropine 1% eye drops (preservative free bottle) | ■ | Mydriatic | | | ✗ | No longer available | |
| homatropine 2% eye drops | ■ | Mydriatic | | | ✗ | No longer available | |
| homatropine 2% eye drops (preservative free bottle) | ■ | Mydriatic | | | ✗ | No longer available | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------------------------------------------------------------------------------|------|------------|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| hyoscine 1/2% eye drops | ■ | Mydriatic | | | ✓ | No longer available | |
| hyoscine 1/8% eye drops | ■ | Mydriatic | | | ✓ | No longer available | |
| Mydrane [Contains tropicamide 0.2mg/ml + phenylephrine 3.1 mg/ml + lidocaine 10mg/ml] solution for injection | ■ | Mydriatic | Rapid dilation prior to cataract surgery, when home dilation has not resulted in adequate mydriasis Intracameral anaesthesia | | | Added by Chair's actions as COVID-19 recovery decision Approved by Chair's actions following cost impact evaluation (5 th June 2024) | |
| Mydriisert ophthalmic insert | ■ | Mydriatic | Maximal pupil dilation pre surgery | | ✓ | | |
| Mydracaine No.1 [Contains procaine hydrochloride 3mg, atropine sulphate 0.5mg, adrenaline acid tartrate 108 micrograms] | ■ | Mydriatic | Treatment of paediatric patients: Rapid dilation of the pupil. Maximal dilation of the pupil in uveitis and iritis. | | ✓ | | |
| Mydracaine No.2 [Contains procaine hydrochloride 6mg, atropine sulphate 1mg, adrenaline acid tartrate 216 micrograms] | ■ | Mydriatic | Treatment of adult patients. Rapid dilation of the pupil. Maximal dilation of the pupil in uveitis and iritis. | | ✓ | | |
| phenylephrine 2.5% single use eye drops | ■ | Mydriatic | Mydriasis for diagnostic or surgical procedures | | ✓ | | |
| phenylephrine 10% single use eye drops | ■ | Mydriatic | | | ✓ | | |
| phenylephrine 0.6% intracameral injection | ■ | Mydriatic | | | ✓ | November 2010 | |
| phenylephrine 2.5% eye drops | ■ | Mydriatic | | | ✓ | No longer available | |
| phenylephrine 5% eye drops | ■ | Mydriatic | | | ✓ | No longer available | |
| tropicamide 0.5% eye drops single use eye drops | ■ | Mydriatic | | Mydriasis and cycloplegia | | ✓ | |
| tropicamide 1% eye drops | ■ | Mydriatic | | | ✓ | | |
| tropicamide 1% eye drops single use eye drops | ■ | Mydriatic | | | ✓ | | |

Vasoconstrictor

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|---------------------------------|------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|----|----|----------|--------|
| adrenaline 0.01% eye drops | ■ | Vasoconstrictor | Vasoconstrictor. To prevent rapid loss of sub-conjunctival injections into the systemic circulation. To control bleeding during surgery | | ✓ | | |
| adrenaline 0.1% eye drops | ■ | Vasoconstrictor | | | ✓ | | |
| ephedrine 0.5% nose drops | | | | | | | |
| xylometazoline 0.05% nose drops | ■ | Vasoconstrictor | | | ✓ | | |
| xylometazoline 0.1% nasal spray | ■ | Vasoconstrictor | | | ✓ | | |

Cytotoxic

Moorfields Pharmacist Handbook
 Cornea and External Disease Induction Manual
 Glaucoma Service Handbook

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------------------|------|------------|--------------------------------------------------------------------------------------------------|------------------------------|----|-------------------------|---------------------------------|
| 5-fluoroURAcil 1% eye drops | ■ | Cytotoxic | Corneal and conjunctival intraepithelial neoplasias/squamous cell carcinoma | | ✓ | April 2019 DTC | |
| fluoroURAcil 10mg in 0.2ml syringe | ■ | Cytotoxic | Post trabeculectomy, when indicated (inhibit cellular proliferation and reduce scarring post-op) | | ✓ | | Moorfields Pharmacists Handbook |
| fluoroURAcil 250mg in 10mL injection | ■ | Cytotoxic | | | ✓ | | |
| fluoroURAcil 500mg in 10mL injection | ■ | Cytotoxic | | | ✓ | | |
| methoTRESate 800 microgram in 0.2mL intravitreal injection | ■ | Cytotoxic | | Primary intraocular lymphoma | | ✓ | |
| mitoMYCin 0.02% eye drops | ■ | Cytotoxic | Laser surgery. Minimises/eradicates post-op haze and scar formation | | ✓ | | |
| mitoMYCin 0.04% eye drops | ■ | Cytotoxic | Conjunctival or corneal squamous cell carcinoma | | ✓ | | |
| mitoMYCin 2mg injection | ■ | Cytotoxic | Intro-operative use, for long-term pressure control. Restricted use. | | ✓ | | |
| mitoMYCin 0.2 mg per mL pre-filled syringe | ■ | Cytotoxic | | | | | |
| mitoMYCin 0.4 mg per mL pre-filled syringe | ■ | Cytotoxic | | | | | |
| tretinoin 0.05% eye drops | ■ | Cytotoxic | Squamous metaplasia and keratinisation of the conjunctiva | | ✓ | Not currently available | |

Ocular Lubricants & Other Eye Drop Preparations

Ocular Lubricant

Others

Ocular Lubricants

MEH Guideline for Ocular Lubricants

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|---------------------------------------------------------|------|----------------------|-------------------------------------------------------------------|----|----|----------|------------------------------------------------------------------------------------------------|
| acetylCYSteine 5% eye drops | ■ | Tear Film Substitute | Tear deficiency, impaired or abnormal mucus production | | ✓ | | BNF 11.8.1; MEH Guideline for Ocular Lubricants; Moorfields Pharmacist Handbook <i>page 35</i> |
| acetylCYSteine 10% eye drops (preservative-free bottle) | ■ | Tear Film Substitute | Tear deficiency, impaired or abnormal mucus production | | ✓ | | |
| carbomer 0.2% eye gel | ■ | Tear Film Substitute | Dry eyes including keratoconjunctivitis sicca, unstable tear film | | ✓ | | |
| carMELlose 0.5% preservative free eye drops | ■ | Tear Film Substitute | Dry eye conditions | | ✓ | | |
| carMELlose 1% preservative free eye drops | ■ | Tear Film Substitute | Dry eye conditions | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------------------------------|------|----------------------|----------------------------------------------------------------------------------------|----|----|--------------------------------------------------------------------------|--------|
| carMELlose sodium 0.5% with glycerine 0.9% eye drops | ■ | Tear Film Substitute | Dry eye conditions For artificial eyes | | ✓ | Jan 2012 DTMMC | |
| hydroxypropyl guar eye drops | ■ | Tear Film Substitute | | | ✓ | July 2010 DTMMC | |
| hypromellose 0.3% eye drops | ■ | Tear Film Substitute | Tear deficiency | | ✓ | | |
| hypromellose 0.3% preservative free eye drops | ■ | Tear Film Substitute | | | ✓ | | |
| hypromellose 0.3% single use eye drops | ■ | Tear Film Substitute | | | ✓ | | |
| hypromellose 0.3% with dextran '70' 0.1% eye drops | ■ | Tear Film Substitute | | | ✓ | | |
| light liquid paraffin eye drops | ■ | Tear Film Substitute | Dry eye conditions | | ✓ | | |
| paraffin eye ointment (with or without vitamin A) | ■ | Tear Film Substitute | Lubricate the eye surface, especially in cases of recurrent corneal epithelial erosion | | ✓ | | |
| paraffin eye ointment lanolin free | ■ | Tear Film Substitute | Ocular Lubricant & protection of the ocular surface (lanolin allergy) | | ✓ | | |
| polyvinyl alcohol 1.4% eye drops (preservative free bottle) | ■ | Tear Film Substitute | Tear deficiency | | ✓ | No longer available | |
| polyvinyl alcohol 1.4% single use eye drops | ■ | Tear Film Substitute | Tear deficiency | | ✓ | | |
| simple eye ointment | ■ | Tear Film Substitute | Lubricate the eye surface, especially in cases of recurrent corneal epithelial erosion | | ✓ | | |
| sodium chloride 0.9% eye drops | ■ | Tear Film Substitute | Irritation, including first-aid removal of harmful substances | | ✓ | No longer available | |
| sodium chloride 0.9% single use eye drops | ■ | Tear Film Substitute | Irritation, including first-aid removal of harmful substances | | ✓ | | |
| sodium hyaluronate 0.1% eye drops | ■ | Tear Film Substitute | Dry eye conditions | | ✓ | | |
| sodium hyaluronate 0.15% with trehalose 3% eye drops | ■ | Tear Film Substitute | Second line option in severe Dry eye conditions | | ✓ | JFC August 2019 | |
| sodium hyaluronate 0.15% single use eye drops | ■ | Tear Film Substitute | | | ✓ | DTC July 2012 | |
| sodium hyaluronate 0.2% eye drops | ■ | Tear Film Substitute | | | ✓ | DTC July 2011 | |
| sodium hyaluronate 0.15% with trehalose 3% and carbomer 0.25% single use eye gel | ■ | Tear Film Substitute | Severe dry eye | | ✓ | JFC August 2019 DTC January 2026 Pan-London ocular lubricant guide | |
| sodium hyaluronate 0.15% with Xanthan gum 1% single use eye GEL | ■ | Tear Film Substitute | Dry eye conditions (Restricted: for scleral lens wearers only) | | ✓ | DTC July 2013 No longer available | |

Others

Cornea and External Disease Induction Manual

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------|------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|------------------------|--------------------------------------------------------------------------------------|
| cyanoacrylate glue | ■ | Other | Plugs corneal perforations, whilst awaiting donor material | | ✓ | | |
| disodium edetate 0.37% eye drops | ■ | Other | Collagenase inhibitor | | ✓ | | Moorfields Pharmacist Handbook page 146 |
| disodium edetate 0.37% or 0.4% lotion | ■ | Other | Chelating agent as an aid to calcified corneal plaque removal | | ✓ | | Moorfields Pharmacist Handbook page 146 |
| disodium edetate 4% solution | ■ | | | | | | |
| ethanol 20% sterile solution | ■ | Other | To assist in the removal of corneal epithelium | | ✓ | | |
| ethanol 70% solution for donor eyes | ■ | | | | | | |
| ethanol absolute sterile solution | ■ | | | | | | |
| glycerol 15% eye drops | ■ | | | | | | |
| glycerol 50% eye drops | ■ | Other | Clearing corneal oedema | | ✓ | Discontinued | Moorfields Pharmacist Handbook page 135 |
| heparin 5,000u/mL eye drops | ■ | | | | | | |
| hyaluronidase 1,500 units injection | ■ | Other | | | ✓ | | |
| insulin (soluble) eye drops 1iu/mL | ■ | Other | A special product of 1 unit of short acting insulin (Humulin S) in 1mL ocular lubricant (Systane®), used in: Persistent epithelial defect in refractory patients who have failed to respond to standard care and second line therapies, or following documented intolerance to primary or second line therapies. | | | DTC approved July 2020 | |
| pilocarpine 0.1% eye drops | ■ | Other | Diagnostic test for Holmes Adie or tonic pupil | | ✓ | | Moorfields Pharmacist Handbook page 95 |
| pilocarpine 5mg tablets | ■ | Other | Dry eyes | | ✓ | | BNF 12.3.5 |
| potassium ascorbate 10% eye drops | ■ | Other | Acid & alkali burns to the cornea | | ✓ | | Moorfields Pharmacist Handbook page 52; Cornea and External Disease Induction Manual |
| sodium chloride 5% preservative free eye drops | ■ | Other | Reduce corneal oedema | | ✓ | | Moorfields Pharmacist Handbook page 135 |
| sodium chloride 5% eye ointment | ■ | Other | Recurrent corneal erosions | | ✓ | | |
| sodium citrate 10.11% eye drops | ■ | Other | Acid & alkali burns to the cornea | | ✓ | | Moorfields Pharmacist Handbook page 52; Cornea and External Disease Induction Manual |
| ceciol® Poly (carboxymethylglucose sulfate) | ■ | Medical device | Treatment of non-healing corneal ulcers/ persistent epithelial defects Restricted: Corneal service only MEH to supply | | | Discontinued Dec 2019 | |
| Tisseel ready to use solutions for sealant | ■ | | | | | | |
| trichloroacetic acid | ■ | | | | | | |

Neovascularisation

| Drug Name | P/L ¹ | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------------------|------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|----|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| aflibercept 40mg in 1mL injection | ■ | AntiVEGF | wet AMD Macular oedema secondary by CRVO/BRVO DMO Myopic CNV | ✓ | ✓ | Joint Formulary Committee Feb 2013 NICE TA Feb 2014 NICE TA July 2015 NICE TA September 2016 NICE TA November 2017 | NICE AMD Technology Appraisal NICE MO CRVO TA NICE MO BRVO TA NICE TA DMO NICE mCNV TA Medical Retina service induction manual 2017; Intravitreal Service Guidelines for the treatment of AMD |
| aflibercept 114.3mg in 1mL injection | ■ | AntiVEGF | wet AMD DMO | ✓ | ✓ | October 2025 DTC April 2026 DTC | NCL wet AMD pathway NCL DMO pathway |
| bevacizumab 1.25mg in 0.05mL syringe | ■ | AntiVEGF | Neovascular glaucoma (DTC June 2008/NCL JFC January 2017) AMD related CNV (DTC September 2009) Non-AMD CNV (DTC Sep 2009) CNV secondary to parafoveal telangiectasia (DTC Aug 2023) Trabeculectomy surgery [sub-conjunctival] (DTC Jan 2015) Retinopathy of prematurity (NCL JFC Feb 2015) – not administered at MEH Familial Exudative Vitreoretinopathy (FEVR) and Coats' disease (DTC November 2015) Pre-operative adjunct to diabetic vitrectomy (DTC January 2017) Submacular haemorrhage Radiation retinopathy (DTC March 2021) Bevacizumab for eyes with late wet AMD and visual acuity better than 6/12 (NCL JFC July 2021) | | ✓ | November 2009 DTC | Intravitreal Service Guidelines for the treatment of AMD |
| bevacizumab 5mg in 0.2mL syringe | ■ | AntiVEGF | Bevacizumab sub-conjunctival injection - corneal neovascularisation | | ✓ | DTC Oct 2011 | Intravitreal Service Guidelines for the treatment of AMD |
| bevacizumab gamma 7.5mg in 0.3mL | ■ | AntiVEGF | wet AMD as last resort in cases of brolocizumab contraindication | | ✓ | October 2025 DTC | NCL wet AMD pathway |
| raniBIZumab 10mg in 1mL injection | ■ | AntiVEGF | wet AMD DMO RVO CNV (Pathological myopia) | ✓ | ✓ | Oct 2012 | NICE Macular oedema (diabetic) Technology Appraisal; NICE AMD Technology Appraisal; Medical Retina service induction manual 2017; Intravitreal Service Guidelines for the treatment of AMD; NICE Macular oedema (retinal vein occlusion Technology Appraisal NICE CNV (pathological myopia) Technology Appraisal |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------|------|------------|---------------------------------------------------------------------------------------------------|----|----|---------------|-----------------------------------------------------------------------------------------------------|
| verTEPorfin 15mg infusion | ■ | Dye | Wet AMD; chronic serous retinopathy; choroidal haemangioma | ✓ | ✓ | December 2007 | NICE TA Macular degeneration (age-related) Intravitreal Service Guidelines for the treatment of AMD |
| brolicizumab 120 mg/ml injection | ■ | AntiVEGF | Wet AMD DMO | ✓ | ✓ | February 2021 | NICE TA (TA672) NICE AMD guideline NICE TA (TA820) |
| faricimab 120 mg/ml injection | ■ | AntiVEGF | DMO Wet AMD Treating visual impairment caused by macular edema after retinal vein occlusion | ✓ | ✓ | June 2022 | NICE TA (TA799) NICE TA (TA800) NICE TA (TA1004) |

Neurological

Botulinum

Systemic

Botulinum

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------|------|------------|-------------------------------------------------------------|----|----|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| botulinum A toxin 100 units injection (BOTOX) | ■ | Neuro | blepharospasm; hemifacial spasm | | ✓ | | BNF 4.9.3; Botulinum Toxin Policy |
| botulinum A toxin 500 units injection (DYSPORT) | ■ | Neuro | Protective ptosis & squint; blepharospasm; hemifacial spasm | | ✓ | DTC Oct 2003 Strabismus service | BNF 4.9.3; Botulinum Toxin by Adnexal Nurse Specialist; Corneal and External Disease Induction Manual; Adnexal Service Manual; Botulinum Toxin Policy |
| botulinum A toxin 50 units injection (XEOMIN) | ■ | Neuro | First line (Adnexal) blepharospasm; hemifacial spasm | | ✓ | July 2012 blepharospasm and hemifacial spasm | BNF 4.9.3 |
| botulinum B toxin (NEUROBLOC) | ■ | Neuro | Non-responders to Type A toxin (Adnexal) | | ✓ | July 2012 blepharospasm and hemifacial spasm | BNF 4.9.3 |

Systemic

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-----------------------------|------|--------------------|---------------------------------------------------------------------------------------------------|----|----|------------------|------------------|
| amitriptyline 10mg tablets | ■ | Antidepressants | Neuropathic pain; post-herpetic neuralgia | | ✓ | | BNF 4.3.1 |
| amitriptyline 25mg tablets | ■ | Antidepressants | | | ✓ | | |
| amitriptyline 50mg tablets | ■ | Antidepressants | | | ✓ | | |
| gabapentin 100mg capsules | ■ | Anticonvulsant | Neuropathic pain; post-herpetic neuralgia | | ✓ | | BNF 4.8.1 |
| gabapentin 300mg capsules | ■ | Anticonvulsant | | | ✓ | | |
| meLATonin 2mg tablets | ■ | Hypnotic | Circadian sleep disorders in the blind | | ✓ | | |
| preGABalin 25mg capsules | ■ | Anticonvulsant | Neuropathic pain; post-herpetic neuralgia | | ✓ | | BNF 4.8.1 |
| pyridostigmine 60mg tablets | ■ | Anticholinesterase | | | ✓ | | |
| idebenone 150mg tablets | ■ | Antioxidants | Treatment of visual impairment in Leber's hereditary optic neuropathy in people 12 years and over | | ✓ | October 2025 DTC | NICE TA (TA1093) |

Diagnostic & Surgical

| | | | | | | |
|---------------------|----------------------------|----------------------------|-------------------------------------------------|-----------------------------------|-------------------------------|----------------------------------|
| Dye | Antiseptic | Irrigation | General Anaesthesia & Gases | Local Anaesthetic | Viscosurgical | Surgical (Other) |
|---------------------|----------------------------|----------------------------|-------------------------------------------------|-----------------------------------|-------------------------------|----------------------------------|

Dye

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------|------|------------|-------------------------------------------------------------------------------------------------------|----|----|-------------|------------------------------------------------------------------------------------------------------------------------------|
| brilliant blue G 0.125mg in 0.5mL syringe | ■ | Dye | Diagnostic examinations | | ✓ | | Moorfields Pharmacist Handbook page 45 |
| fluorescein sodium 2% single use eye drops | ■ | Dye | | | ✓ | | |
| trypan blue 0.15% with brilliant blue G 0.025% injection | ■ | Dye | | | ✓ | | |
| fluorescein 10% injection | ■ | Dye | Ophthalmic angiography including examination of the fundus and iris vasculature, sclera and episclera | | ✓ | | Moorfields Pharmacist Handbook page 4; Adult IV Fluorescein Angiography Policy; Paediatric IV Fluorescein Angiography Policy |
| fluorescein sodium 20% injection | ■ | Dye | | | ✓ | | |
| indocyanine green 25mg injection | ■ | Dye | Ophthalmic angiography of choroidal vasculature | | ✓ | | Adult IV ICG Angiography Policy |
| methylene blue 10mg/mL ampoule | | | | | | | |
| trypan blue 0.06% injection | ■ | Dye | Diagnostic examinations | | ✓ | August 2003 | |

Antiseptic

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------|------|------------|---------------------------------------------------------------------------------|----|----|----------|-----------------------------------------|
| chlorhexidine 0.015% cetrimide 0.15% sachets | ■ | Antiseptic | Skin disinfection | | ✓ | | BNF 13.11.2 |
| hydrogen peroxide 6% solution | ■ | Antiseptic | For skin disinfection, particularly cleansing and deodorising wounds and ulcers | | ✓ | | BNF 13.11.6 |
| iodine tincture | ■ | Antiseptic | Skin disinfection | | ✓ | | BNF 13.11.4 |
| povidone iodine 5% eye drops | ■ | Antiseptic | Antiseptic prior to surgical procedures | | ✓ | | Moorfields Pharmacists Handbook page 71 |
| povidone iodine 10% antiseptic solution | ■ | Antiseptic | Skin disinfection | | ✓ | | BNF 13.11.4 |

Irrigation

| Drug Name | P/L [†] | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------|------------------|------------|---------------------------------------------------------|----|----|----------------|--------|
| balanced salt solution 15 mL | ■ | Irrigation | Surgical Procedures | | ✓ | | |
| balanced salt solution 500mL | ■ | Irrigation | | | ✓ | | |
| compound sodium lactate 500mL infusion | ■ | Irrigation | | | ✓ | | |
| compound sodium lactate 1000mL infusion | ■ | Irrigation | | | ✓ | | |
| sodium chloride 0.9% irrigation sachets | ■ | Irrigation | | | ✓ | | |
| sodium chloride 0.9% sterile eye irrigation 1L bag | ■ | Irrigation | | | ✓ | | |
| sodium chloride 0.9% sterile irrigation 1L bottle | ■ | Irrigation | | | ✓ | | |
| STERIMAR | ■ | Irrigation | As a nasal douche following dacryocystorhinostomy (DCN) | | ✓ | DTMMC Jan 2013 | |

General Anaesthesia & Gases

| Drug Name | P/L [†] | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------|------------------|---------------------|------------------------------------------------------------|----|----|----------|----------|
| desflurane volatile liquid | ■ | General anaesthesia | Induction of anaesthesia | | ✓ | | BNF 15.1 |
| isoflurane volatile liquid | ■ | General anaesthesia | | | ✓ | | |
| sevoflurane volatile liquid | ■ | General anaesthesia | | | ✓ | | |
| alfentanil 1mg in 2mL injection | ■ | General anaesthesia | Analgesic supplement for use before and during anaesthesia | | ✓ | | |
| atracurium 25mg in 2.5mL injection | ■ | General anaesthesia | | | ✓ | | |
| atracurium 50mg in 5mL injection | ■ | General anaesthesia | | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-----------------------------------------------------------------------------|------|----------------------|------------------------------------------------------------------------------------|----|--------|-------------------------------|--------|
| dexmedetomidine 100 micrograms in 1mL concentrate for solution for infusion | ■ | Anaesthesia adjuvant | Procedural awake sedation [Intranasal] Pre-medication for paediatrics >1 year | | ✓ ✓ | DTC Feb 2019 DTC July 2021 | |
| glycopyrronium 200 microgram in 1mL injection | ■ | General anaesthesia | | | ✓ | | |
| glycopyrronium 500 micrograms with neostigmine 2.5mg in 1mL injection | ■ | General anaesthesia | | | ✓ | | |
| glycopyrronium 600 microgram in 3mL injection | ■ | General anaesthesia | | | ✓ | | |
| ketamine 10mg in 1mL injection | ■ | General anaesthesia | Induction of anaesthesia | | ✓ | | |
| neostigmine 2.5mg in 1mL injection | ■ | General anaesthesia | Neuromuscular blockade | | ✓ | | |
| proPOFol 1% injection | ■ | General anaesthesia | Induction of anaesthesia | | ✓ | | |
| proPOFol 2% injection | ■ | General anaesthesia | | | ✓ | | |
| proPRANolol 1mg in 1mL injection | ■ | General anaesthesia | Used during surgery to control tachycardia | | ✓ | | |
| remifentanyl 1mg injection | ■ | General anaesthesia | Analgesic agent for use during induction and/or maintenance of general anaesthesia | | ✓ | | |
| rocuronium 50mg in 5mL injection | ■ | General anaesthesia | Neuromuscular blockade | | ✓ | | |
| sugammadex 100mg in 1mL injection | ■ | General anaesthesia | Reversal of neuromuscular blockade | | ✓ | DTMMC Apr 2013 | |
| suxamethonium 100mg in 2mL injection | ■ | General anaesthesia | Neuromuscular blockade | | ✓ | | |
| thiopental 500mg injection | ■ | General anaesthesia | Induction of anaesthesia | | ✓ | | |
| vecuronium 10mg injection | ■ | General anaesthesia | Neuromuscular blockade | | ✓ | | |
| air SIZE F | | | | | | | |
| air SIZE G | | | | | | | |
| air SIZE J | | | | | | | |
| nitrous oxide SIZE E | ■ | General anaesthesia | Maintenance of anaesthesia and analgesia | | ✓ | | |
| nitrous oxide SIZE G | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE C | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE CD | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE D | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE E | ■ | General anaesthesia | | | ✓ | | |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|--------------------------|------|---------------------|----------------------|----|----|----------|--------|
| oxygen SIZE F | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE G | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE HX | ■ | General anaesthesia | | | ✓ | | |
| oxygen SIZE J | ■ | General anaesthesia | | | ✓ | | |
| perfluoropropane gas | | | | | | | |
| sulphur hexafluoride gas | | | | | | | |

Local Anaesthetic

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------------------------|------|-------------------|---------------------------------------------------------------------------------------------------------------------------------|----|----|------------------------|--------------------------------------------------|
| bupivacaine 0.5% injection | ■ | Local Anaesthetic | | | | | |
| bupivacaine 0.25% and adrenaline 1 in 200,000 injection | ■ | Local Anaesthetic | Lid surgeries requiring local anaesthetic | | ✓ | | |
| bupivacaine 0.5% and adrenaline 1 in 200,000 injection | ■ | Local Anaesthetic | Lid surgeries requiring local anaesthetic | | ✓ | | |
| cocaine 4% eye drops | ■ | Local Anaesthetic | Surface anaesthesia when conditions also require pupil dilation or vasoconstriction. Diagnosis of Horner's syndrome. | | ✓ | | Moorfields Pharmacist Handbook page 48, BNF 15.2 |
| cocaine 10% solution | ■ | Local Anaesthetic | | | | | |
| cocaine 5% nasal solution spray | ■ | Local Anaesthetic | Anaesthetic during DCR surgery | | | DTMMC Jan 2026 | |
| EMLA lidocaine 25mg/g and prilocaine 25mg/g cream | ■ | Local Anaesthetic | | | | | |
| lidocaine 3.5% eye gel | ■ | Local Anaesthetic | Strabismus surgery only | | ✓ | DTMMC Oct 2014 | |
| lidocaine 2% injection | ■ | Local Anaesthetic | | | | | |
| lidocaine 2% injection and adrenaline 1 in 200,000 injection | ■ | Local Anaesthetic | | | | | |
| lidocaine 5% and phenylephrine 0,5% nasal spray | ■ | Local Anaesthetic | | | | | |
| lidocaine 4% and fluorescein 0.25% single use eye drops | ■ | Local Anaesthetic | | | | | |
| oxybuprocaine 0.4% single use eye drops | ■ | Local Anaesthetic | Surface anaesthesia | | ✓ | | Moorfields Pharmacist Handbook page 48, BNF 15.2 |
| proxymetacaine 0.5% single use eye drops | ■ | Local anaesthetic | | | ✓ | | |
| proxymetacaine 0.5% with fluorescein 0.25% single use eye drops | ■ | Local anaesthetic | Surface anaesthesia and staining | | ✓ | No longer manufactured | |
| tetracaine 1% single use eye drops | ■ | Local Anaesthetic | Surface anaesthesia | | ✓ | | |
| tetracaine 4% gel | ■ | Local Anaesthetic | | | | | |

Viscosurgical

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------------|------|---------------|----------------------------------------------------------------------------------------------------------------------------------------|----|----|----------|------------------------------------------|
| HPMC 2% in balanced salt solution injection | ■ | Viscosurgical | Protection of ocular structures and maintenance of anterior chamber depth during surgical procedures | | ✓ | | Moorfields Pharmacists Handbook page 140 |
| silicone oil 1,300 cps injection | ■ | Viscosurgical | Intraocular tamponade | | ✓ | | Moorfields Pharmacists Handbook page 140 |
| sodium hyaluronate 10mg in 1mL intraocular injection | ■ | Viscosurgical | Surgical procedures on the eye including cataract extraction. Protection of ocular structure within the anterior or posterior chamber. | | ✓ | | Alcon Product Information |
| sodium hyaluronate 14mg in 1mL intraocular injection | ■ | Viscosurgical | | | ✓ | | |
| sodium hyaluronate 23mg in 1mL intraocular injection | ■ | Viscosurgical | | | ✓ | | |

Surgical other

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|----------------------------------------------------------------------------|------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----|----|----------------------|-----------------------------------------------|
| acetylcholine 20mg powder for intraocular irrigation | ■ | | | | | | |
| Holoclar 79,000 - 316,000 cells/cm ² living tissue equivalent ▼ | ■ | Miscellaneous | Moderate to severe limbal stem cell deficiency after eye burns | ✓ | | NICE TA Aug 2017 | NICE technology appraisal |
| Juvederm Ultra 3 / Juvederm Ultra 4 | ■ | Dermal filler | Reconstructive surgery / socket volume augmentation | | ✓ | DTMMC Oct 2014 | |
| ocriplasmin | ■ | Miscellaneous | Vitreomacular traction. As per NICE TA 297 | ✓ | ✓ | NICE TA Oct 2013 | NICE Technology Appraisal |
| perfluoro-octane pre-filled syringe | | | | | | | |
| perfluoro-decalin pre-filled syringe | ■ | | To improve the visibility of the retina during surgery in the vitreous cavity of the eye | | | | |
| tissue plasminogen activator (TPA) / rTPA /alteplase | ■ | Miscellaneous | Ophthalmic fibrinolysis | | ✓ | | Moorfields Pharmacists Handbook page 110 |
| tranexamic acid 500mg Solution for Injection | ■ | Antifibrinolytic | Antifibrinolytic use pre-surgery (Dacryocystorhinostomy and procedures causing more invasive intraoperative bleeding of nasal mucosa) | | | | |
| tranexamic acid 500mg tablet | ■ | Antifibrinolytic | Post-op prevention of excessive, localised haemorrhage | | | | |
| voretigene neparvovec 1.5x10 ¹¹ vg ▼ | ■ | Miscellaneous | Treatment of RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed | ✓ | | NICE HST 11 Oct 2019 | NICE Highly Specialised Technologies Guidance |

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-----------|------|------------|-----------------------------------------------------------------------------------------------|----|----|----------|--------|
| | | | biallelic RPE65 mutations and who have sufficient viable retinal cells. As per NICE HST 11 | | | | |

Other (Systemic)

Bisphosphonates

Gastrointestinal

Analgesics

Nutrition

Bisphosphonates

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------|------|-----------------|------------------------------|----|----|----------|----------------------------------------------------------------------------------------|
| alendronic acid 70mg tablets | ■ | Bisphosphonates | Steroid-induced osteoporosis | ✓ | ✓ | | NICE Technology Appraisal; Clinical Knowledge Summaries; National Osteoporosis Society |

Gastro-intestinal

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-----------------------------------------|------|-------------------------------|-----------------------------------------------------------|----|----|----------|-----------|
| cyclizine 50mg tablets | ■ | Anti-histamine | Nausea and vomiting | | ✓ | | BNF 5.1 |
| metoclopramide 10mg tablets | ■ | Dopamine receptor antagonists | Nausea and vomiting | | ✓ | | BNF 5.1 |
| omeprazole 20mg capsules | ■ | PPI | Prophylaxis of NSAID-associated gastric or duodenal ulcer | | ✓ | | BNF 1.3.5 |
| omeprazole 20mg dispersible tablets | ■ | PPI | | | ✓ | | |
| ondansetron 4mg tablets | ■ | 5HT3 receptor antagonists | Nausea and vomiting | | ✓ | | BNF 5.1 |
| propantheline 15mg tablets | ■ | | | | | | |
| ranitidine 150mg tablets | ■ | Histamine Antagonist | Prophylaxis of NSAID-associated gastric or duodenal ulcer | | ✓ | | BNF 1.3.1 |
| ranitidine 75mg in 5mL sugar free syrup | ■ | Histamine antagonist | | | ✓ | | |

Analgesics

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|------------------------------------------------|------|------------|-------------------------------------|----|----|----------|---------|
| aspirin 300mg dispersible tablets | ■ | Analgesic | Pain and inflammation; antiplatelet | | ✓ | | BNF 2.9 |
| aspirin 75mg dispersible tablets | ■ | Analgesic | Antiplatelet | | ✓ | | |
| aspirin 75mg enteric-coated tablets | ■ | Analgesic | | | ✓ | | |
| co-CODamol 30/500 capsules | ■ | Analgesic | Pain relief | | ✓ | | BNF 4.7 |
| co-CODamol 8/500 effervescent tablets | ■ | Analgesic | | | ✓ | | |
| co-CODamol 8/500 tablets | ■ | Analgesic | | | ✓ | | |
| codeine 15mg in 5mL linctus | ■ | Analgesic | | | ✓ | | |
| codeine phosphate 15mg tablets | ■ | Analgesic | | | ✓ | | |
| codeine phosphate 30mg tablets | ■ | Analgesic | | | ✓ | | |
| coDyDramol 10/500 tablets | ■ | Analgesic | | | ✓ | | |
| dihydrocodeine 30mg tablets | ■ | Analgesic | | | ✓ | | |
| morphine sulphate 10mg in 5mL solution | ■ | Analgesic | | | ✓ | | |
| paracetamol 120mg in 5mL sugar free suspension | ■ | Analgesic | | | ✓ | | |
| paracetamol 250mg in 5mL sugar free suspension | ■ | Analgesic | | | ✓ | | |
| paracetamol 500mg soluble tablets | ■ | Analgesic | | | ✓ | | |
| paracetamol 500mg tablets | ■ | Analgesic | | | ✓ | | |
| paracetamol 120mg suppositories | ■ | Analgesic | | | ✓ | | |
| paracetamol 240mg suppositories | ■ | Analgesic | | | ✓ | | |
| paracetamol 500mg suppositories | ■ | Analgesic | | | ✓ | | |
| tramadol 50mg capsules | ■ | Analgesic | | | ✓ | | |

Nutrition

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------------------|------|------------|----------------------------------------------------------------------------------------------------------------------------|----|----|--------------|----------------------------------------------------------------------------------|
| ascorbic acid 500mg tablets | ■ | Vitamin | Oral supplement (with topical drops) for acid or alkaline burns to the cornea | | ✓ | | BNF 9.6.3; Moorfields Pharmacists Handbook page 52 |
| ascorbic acid 50mg tablets | ■ | Vitamin | | | ✓ | | |
| calcium carbonate 1.25g chewable tablets | ■ | Calcium | Primary prevention of osteoporosis | ✓ | ✓ | | BNF 9.5.1; NICE Technology Appraisal; SIGN Osteoporosis |
| calcium carbonate D3 chewable tablets | ■ | Calcium | | ✓ | ✓ | | |
| calcium carbonate D3 FORTE chewable tablets | ■ | Calcium | | ✓ | ✓ | | |
| folinic acid (as calcium folinate) 15mg tablets | ■ | Calcium | Counteract the folate-antagonist action of pyrimethamine and sulfadiazine | | ✓ | | BNF 8.1; MEH Anti-infective Guidelines; Moorfields Pharmacists Handbook page 114 |
| folic acid 5mg tablets | ■ | Anaemia | Prevention of methotrexate-induced side-effects | | ✓ | | BNF 9.1.2; SPSS |
| folic acid 2.5mg/5ml solution | ■ | Anaemia | Prevention of methotrexate-induced side-effects | | ✓ | Aug 2023 DTC | BNF 9.1.2 |
| pyridoXINe 10mg tablets | ■ | Vitamin | Deficiency states, isoniazid- or pencillamine-induced neuropathy, idiopathic sideroblastic anaemia, premenstrual syndrome. | | ✓ | | BNF 9.6.2 |
| pyridoXINe 50mg tablets | ■ | Vitamin | | | ✓ | | |
| thiamine 100mg tablets | ■ | Vitamin | Vitamin B ₁ deficiency | | ✓ | | |
| Vitamin A (retinol) (oral) | ■ | Vitamin | Vitamin A deficiency (first-line) | | ✓ | | |
| Vitamin A (retinol) Intramuscular | ■ | Vitamin | Patients with malabsorption issues who remain deficient despite trialling oral vitamin A | | ✓ | | |

Thyroid Dysfunction

| Drug Name | P/L† | Drug Class | Formulary Indication | N* | L* | Comments | Source |
|-------------------------------------|------|--------------|---------------------------|----|----|------------------|-----------|
| Levothyroxine 25micrograms tablets | ■ | Hormone | Hypothyroidism | ✓ | | DTMMC April 2022 | BNF 6.2.1 |
| Levothyroxine 50micrograms tablets | ■ | Hormone | | ✓ | | DTMMC April 2022 | BNF 6.2.1 |
| Levothyroxine 100micrograms tablets | ■ | Hormone | | ✓ | | DTMMC April 2022 | BNF 6.2.1 |
| Propylthiouracil 50mg tablets | ■ | Anti-thyroid | Hyperthyroidism | ✓ | | DTMMC April 2022 | BNF 6.2.2 |
| Propranolol 10mg tablets | ■ | Beta-Blocker | Adjunct in thyrotoxicosis | ✓ | | DTMMC April 2022 | BNF 6.2.2 |
| Carbimazole 5mg tablets | ■ | Anti-thyroid | Hypethyroidism | ✓ | | DTMMC April 2022 | BNF 6.2.2 |
| Carbimazole 20mg tablets | ■ | Anti-thyroid | | ✓ | | DTMMC April 2022 | BNF 6.2.2 |

Appendix 1 – Fact Sheets (Unlicensed Medication)

General Recommendations

The use of Preservative Free Products over Preserved Ones may be recommended even when there is no allergy to preservatives. This often applies to:

- Patients who are on many different preserved drops at the same time
 - Patients who need drops with high frequency
 - Patients on long term therapy
 - Patients with compromised cornea e.g. corneal dystrophies, grafts, burns
-
- The rationale behind this is that preservatives can be toxic to the eye so the use of too much of it or for long term should be avoided when possible
 - Unpredictable sensitivity to any component of a topical eye formulation should always be borne in mind. Sometimes patients may experience stinging, discomfort or blurred vision. This may lead to complaints and compliance issues
 - The choice of artificial tear solution is partly subjective as to which one best controls the symptoms. Often patients try many lubricants until they find the one which works for them.
 - If any product change is considered then patient approval should always be requested

These Fact Sheets are to be considered as information on what is current practice at Moorfields Eye Hospital. They are not to be intended as guidelines

Developed by:

Medicines Information Team / Formulary Team 02075662369
Moorfields Eye Hospital NHS Foundation Trust
City Road, London, EC1V 2PD

For more detailed information please refer to:

Moorfields Eye Hospital NHS Foundation Trust Pharmacists Handbook 2006

Contents

Contents

*Ciclosporin A 0.2%
(Preservative Free) eye
ointment*

*Polihexanide 0.02% and 0.06%
(Preservative Free) PHMB eye
drops*

Ciclosporin 0.2% (Preservative Free) eye ointment

Presentation: 3.5 g tube (available as unlicensed special or POM-V product)

Uses: Management of severe allergic eye disease. Severe dry eye syndromes. Prevention of corneal graft rejection
Autoimmune keratoconjunctivitis e.g. vernal, atopic, staphylococcal hypersensitivity
Thygeson's keratitis, Ligneous conjunctivitis. Non healing corneal erosions

Rationale for use: No licensed alternative available e.g. Patients intolerant to any of the excipients in the ciclosporin eye drop formulation

Dose: Apply 2 to 4 times a day

Expected length of treatment: Various, it depends on the patient diagnosis, often long term

Cautions: Wash hands after use

Do not use in pregnancy

Do not use when there is fungal disease of the eye

Contact lens wear to be avoided except after specialist recommendation

Side effects: Mild irritation in the first few days of therapy may occur

Monitoring: The drug does not require any special monitoring as systemic adsorption is minimal

Storage: Store below 25°C. Discard one month after opening.

Other information: The unlicensed special medicine and the licensed animal medicine have both been manufactured to the same exact standards as for licensed human medicines

Useful when patients cannot tolerate eye drops

Contains paraffin base, maize oil and lanolin alcohol

Ordered from: Directly from unlicensed special distributor or from veterinary wholesaler

Polihexanide 0.02% and 0.06% (Preservative Free) eye drops (Polyhexamethylene biguanide) PHMB

Presentation: 10ml multidose bottle

Uses: Acanthamoeba Keratitis infections usually in contact lenses users

Rationale for use: No licensed alternative available

Dose: Depends on severity of condition:

1 drop every hour day and night for 2 days, then every hour day only for 3 days.

Intensive treatment is used at an early stage, while organisms are susceptible and before cysts have fully matured.

Reduce to 3 hourly, then tailor thereafter according to the course of the disease

Expected length of treatment: Treatment must be prolonged in order to eradicate cysts

Cautions: None listed

Side effects: Toxicity with PHMB is rare

Monitoring: The drug does not require any special monitoring

Storage: Store below 25°C. Discard four weeks after opening

Other information: Used in combination with propamidine 0.1% or hexamidine 0.1% eye drops